“`html

Gene Therapy for Wiskott-Aldrich Syndrome Nears EU Approval

A gene therapy for the treatment of wiskott-Aldrich syndrome, a rare and severe form of immunodeficiency that affects immune function and bleeding control, is approaching approval at the European level. This could offer patients a long-awaited therapeutic option in a context were available treatments are limited, with clinical data indicating a notable reduction in major complications.

Understanding Wiskott-Aldrich Syndrome

The European Medicines Agency (EMA) has recommended the authorization in the European Union (EU) of the gene therapy Waskyra (etuvetigene autotemcel) for the treatment of patients aged at least 6 months, diagnosed with Wiskott-Aldrich syndrome (WAS) who have mutations in the WAS gene and for whom hematopoietic stem cell transplantation is indicated, but there is no compatible donor.

Wiskott-aldrich syndrome is a rare hereditary disease, present almost exclusively in males, characterized by abnormalities of blood cells and those of the immune system, caused by the lack of a functional WAS protein.

This deficiency causes both a decrease in the number of platelets, with an increased risk of bruising and bleeding, and a severe immune deficiency, making individuals highly susceptible to infections. Symptoms typically appear in infancy and can be life-threatening.

How waskyra Gene Therapy Works

Waskyra is a type of gene therapy called an *ex vivo* gene therapy. This means that cells are taken from the patient, genetically modified in a laboratory, and then returned to the patient’s body. Specifically,Waskyra uses a viral vector (a modified virus) to deliver a functional copy of the WAS gene into the patient’s own hematopoietic stem cells – the cells that give rise to all blood cells.

These modified cells are then infused back into the patient after they have undergone chemotherapy to make space for the new, corrected cells. The goal is for these corrected cells to repopulate the bone marrow and produce functional WAS protein, thereby restoring immune function and platelet counts.

Clinical Trial Results and EMA Recommendation

The EMA’s recommendation is based on data from a clinical trial that demonstrated significant improvements in patients treated with Waskyra. Key findings include a considerable reduction in the rate of severe infections and autoimmune manifestations, as well as improvements in platelet counts. The therapy showed a significant reduction in major complications associated with WAS.

The EMA noted that Waskyra’s benefits outweigh its risks, especially for patients who lack a suitable donor for a stem cell transplant. Stem cell transplantation remains the curative treatment for WAS, but finding a matched donor can be challenging.

What This Means for Patients

For patients with Wiskott-Aldrich syndrome who do not have a compatible donor for a stem cell transplant, Waskyra represents a potentially life-changing treatment option. It offers the possibility of restoring immune function, reducing bleeding risk, and improving overall quality of life. the EMA’s recommendation is a significant step towards making this therapy available to those who need it most.

key takeaways

• Waskyra is a gene therapy for Wiskott-Aldrich syndrome.
• It’s designed for patients without a compatible stem cell donor.
• The therapy involves modifying the patient’s own stem cells to produce functional WAS protein.
• clinical trials show a reduction in severe complications and improvements in platelet counts.
• The EMA has recommended its approval in the EU.

The final decision on approval rests